Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Taxus launch in Japan

This article was originally published in The Gray Sheet

Executive Summary

Boston Scientific launches its Taxus Express2 paclitaxel-eluting stent in Japan May 8. The firm secured reimbursement from Japan's National Health Insurance System May 1 for the device, which gained Ministry of Health, Labor and Welfare approval in late March. Taxus joins Johnson & Johnson/Cordis' Cypher, the only drug-eluting stent on the Japanese market (1"The Gray Sheet" April 9, 2007, p. 17)...

You may also be interested in...

Boston Scientific’s Taxus Express2 To Make Long-Awaited Debut In Japan

Boston Scientific expects to launch its Taxus Express2 paclitaxel-eluting stent in Japan in four to six weeks, once the Japanese Ministry of Health, Labor and Welfare establishes reimbursement for the device

Could Revisiting US Approval Decisions Become Less Rare?

While not identifying specific situations raising potential questions, the FDA commissioner uses his appearance at agency's annual rare disease event to advise regulatory decisions may be revisited as more data becomes available. 

NGM’s Pan-FGF Receptor Approach In NASH Shows Benefits And Drawbacks

NGM’s Phase II data for FGF19 analog aldafermin shows ability to reduce liver fat and improve fibrosis, but also raises LDL-C. Company says it gets a broader effect this way and can manage the increased cholesterol.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts